After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing

Athena Countouriotis, Avenzo Therapeutics CEO (via BioMarin) June 1, 2026 10:11 AM EDT StartupsDealsChina Af­ter be­ing ditched by Can­did, Rally­bio finds Aven­zo to take its Nas­daq list­ing Kyle LaHucik Biotech Correspondent Aven­zo Ther­a­peu­tics, one of the first biotechs to get ma­jor West­ern VC back­ing to in-li­cense Chi­nese as­sets, will go pub­lic in a re­verse merg­er with … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER